Houlihan Lokey Reports Second Quarter Fiscal 2027 Financial Results

Houlihan Lokey reported fiscal second-quarter revenue of $692 million, up $32 million (about 4.8%) from $660 million a year earlier. Net income attributable to the company was $109 million, down from $111 million; diluted EPS was $1.64, with the prior-year comparison cut off in the supplied text.

Analysis

The excerpt supports a restrained read, not a high-conviction earnings trade: revenue increased while net income was slightly lower, but the release is truncated and does not establish whether the divergence reflects business mix, compensation, taxes, or other costs. For an advisory firm, the key second-order question is whether incremental revenue converts to earnings as deal activity improves; headline revenue alone cannot answer that. Near term, HLI may trade more on the full release’s segment mix, margins, and outlook than on the reported top line. Over 1–3 months, monitor announced M&A and financing activity, restructuring demand, and management’s commentary on pipeline conversion. Over 6–18 months, a sustained recovery in transaction activity could improve utilization and earnings conversion, while renewed deal delays could leave costs ahead of revenue. Competitors including Evercore, Lazard, and PJT Partners face similar cycle exposure; relative performance may hinge on business mix, which this excerpt does not provide. The contrarian point is that modest revenue growth is not necessarily earnings inflection: without evidence of improving margins or forward bookings, extrapolating a broader advisory recovery would be premature. The thesis would strengthen with improving segment profitability and pipeline conversion, and weaken if guidance or margins deteriorate.

Key Decisions for Investors

• No immediate directional position on this excerpt alone; wait for the complete release and call rather than treating revenue growth as proof of earnings momentum.
• Set an alert for segment revenue, adjusted operating margin or compensation ratio, and forward pipeline commentary. These are the missing data needed to assess whether incremental revenue is converting to profit.
• For a 1–3 month relative-value watch, compare HLI’s subsequent margin and pipeline disclosures with Evercore, Lazard, and PJT Partners; consider a relative position only if HLI’s earnings conversion diverges materially from peers.
• Falsification: downgrade the recovery thesis if management signals weaker deal conversion or if margins fall despite continued revenue growth; upgrade it only if the full results show improving profitability and a credible pipeline.